Found: 10
Select item for more details and to access through your institution.
P-164: Safety of lenalidomide (LEN)-based therapy vs non–LEN-based therapy for transplant-ineligible newly diagnosed multiple myeloma (TNE NDMM): update from the post-authorization study MM-034.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S125, doi. 10.1016/S2152-2650(21)02291-6
- By:
- Publication type:
- Article
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pomalidomide and Dexamethasone Treatment for ≥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e284, doi. 10.1016/j.clml.2019.09.468
- By:
- Publication type:
- Article
European Post-Authorization Safety Study of Patients With Relapsed or Refractory Multiple Myeloma Treated With Pomalidomide in a Real-World Setting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e256, doi. 10.1016/j.clml.2019.09.423
- By:
- Publication type:
- Article
Post-Authorization Safety Study of Lenalidomide-Based vs Non–Lenalidomide-Based Treatment in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e226, doi. 10.1016/j.clml.2019.09.376
- By:
- Publication type:
- Article
European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e65, doi. 10.1016/j.clml.2017.03.118
- By:
- Publication type:
- Article
European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e62, doi. 10.1016/j.clml.2017.03.113
- By:
- Publication type:
- Article
Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e145, doi. 10.1016/j.clml.2017.03.261
- By:
- Publication type:
- Article
Stress-related psycho-physiological disorders: randomized single blind placebo controlled naturalistic study of psychometric evaluation using a radio electric asymmetric treatment.
- Published in:
- 2011
- By:
- Publication type:
- journal article
A new approach on stress-related depression & anxiety: Neuro-Psycho- Physical-Optimization with Radio Electric Asymmetric-Conveyer.
- Published in:
- Indian Journal of Medical Research, 2010, v. 132, n. 2, p. 189
- By:
- Publication type:
- Article